新辅助纳武利尤单抗改变可切除胶质母细胞瘤的肿瘤免疫微环境
本研究为单臂II期临床试验(NCT02550249),在30例胶质母细胞瘤手术患者中测试术前给予纳武利尤单抗、术后继续用药直至疾病进展或不可耐受毒性。新辅助纳武利尤单抗增强了趋化因子转录本表达、提高了免疫细胞浸润并增加了肿瘤浸润T淋巴细胞的TCR克隆多样性,支持其局部免疫调节作用。挽救手术组未见明显临床获益,但3例原发手术患者中2例在33和28个月后仍存活。
要点
- 术前给予纳武利尤单抗可增强胶质母细胞瘤肿瘤免疫微环境的免疫细胞浸润和TCR克隆多样性。
- 新辅助纳武利尤单抗在可切除胶质母细胞瘤中显示出局部免疫调节效应。
- 挽救手术组未见明显临床获益,原发手术组3例中2例长期存活。
核心结论
- 新辅助纳武利尤单抗可调节可切除胶质母细胞瘤的肿瘤免疫微环境,表现为趋化因子转录本表达增强、免疫细胞浸润增高和TCR克隆多样性增加。
- 挽救手术患者未见明显临床获益,但原发手术患者中有2例在33和28个月后仍存活。
研究设计与样本
- 单臂II期临床试验(NCT02550249),纳入30例胶质母细胞瘤患者,其中27例为复发挽救手术、3例为新诊断原发手术。
- 术前给予一剂纳武利尤单抗,术后继续纳武利尤单抗直至疾病进展或不可接受毒性。
- 利用纳武利尤单抗给药前后及未接受纳武利尤单抗患者的肿瘤组织,通过多种分子和细胞分析评估肿瘤免疫微环境变化。
主要发现
- 新辅助纳武利尤单抗导致趋化因子转录本表达增强。
- 新辅助纳武利尤单抗导致免疫细胞浸润增高。
- 新辅助纳武利尤单抗导致肿瘤浸润T淋巴细胞的TCR克隆多样性增加。
- 挽救手术组未见明显临床获益。
- 3例原发手术患者中2例在33和28个月后仍存活。
临床怎么用
- 新辅助纳武利尤单抗在可切除胶质母细胞瘤中具有局部免疫调节效应,支持进一步探索PD-1阻断在该病中的免疫治疗策略。
- 挽救手术场景下未观察到明显临床获益,原发手术场景的长期存活信号需更大样本验证。
局限性
- 单臂设计,样本量30例,其中原发手术仅3例,无法确立临床获益。
- 挽救手术组未见明显临床获益,原发手术组长存活仅为个别观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiological effects of PD-1 blockade in patients undergoing surgery for glioblastoma, we conducted a single-arm phase II clinical trial (NCT02550249) in which we tested a presurgical dose of nivolumab followed by postsurgical nivolumab until disease progression or unacceptable toxicity in 30 patients (27 salvage surgeries for recurrent cases and 3 cases of primary surgery for newly diagnosed patients). Availability of tumor tissue pre- and post-nivolumab dosing and from additional patients who did not receive nivolumab allowed the evaluation of changes in the tumor immune microenvironment using multiple molecular and cellular analyses. Neoadjuvant nivolumab resulted in enhanced expression of chemokine transcripts, higher immune cell infiltration and augmented TCR clonal diversity among tumor-infiltrating T lymphocytes, supporting a local immunomodulatory effect of treatment. Although no obvious clinical benefit was substantiated following salvage surgery, two of the three patients treated with nivolumab before and after primary surgery remain alive 33 and 28 months later.
引用
- Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019. PMID: 30742120. doi:10.1038/s41591-018-0339-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。